The Middle East and Africa Artificial Intelligence (AI) in drug discovery market was valued at USD 117.20 million in 2025 and is projected to reach USD 2,569.38 million by 2033, growing at a CAGR of 47.1% from 2026 to 2033. The market is witnessing steady expansion driven by increasing investment in healthcare digitalization, growing interest in precision medicine, and rising adoption of AI-enabled platforms to accelerate drug discovery timelines and reduce R&D costs.
The region is experiencing growing collaborations between pharmaceutical companies, research institutions, and technology providers to integrate AI, machine learning, and big data analytics into early-stage drug development. Governments across the Middle East are actively supporting healthcare innovation initiatives, while select African markets are gradually adopting advanced computational biology tools. The increasing burden of chronic diseases, along with the need for faster and more cost-efficient drug development processes, is encouraging stakeholders to shift toward AI-powered drug discovery solutions, enhancing target identification, lead optimization, and clinical trial effi